Pelthos Therapeutics Inc.
PTHS · XNYSCIK 1919246fmd_1JKJ9EGT0RR7J53V1QF3M71BZXManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2022 to Sep 30, 2026, 16 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | – | – | 0 | 17 |
| Cost of revenue | – | – | 0 | 4 |
| Gross profit | – | – | 0 | 13 |
| Research and development | 0 | 3 | 1 | 1 |
| Selling, general and administrative | – | – | 6 | 42 |
| Total operating expenses | 2 | 7 | 8 | – |
| Operating income | (2) | (7) | (8) | (32) |
| Interest expense | 0 | 0 | 1 | 3 |
| Interest and investment income | – | – | 0 | 0 |
| Other non-operating income (expense) | (0) | (1) | (0) | (18) |
| Income before taxes | (2) | (7) | (8) | (51) |
| Income tax expense | – | – | 0 | (7) |
| Net income from continuing operations | – | – | (8) | (43) |
| Net income | (2) | (7) | (8) | (43) |